Incannex Healthcare Inc

Incannex Healthcare Ltd. is a clinical stage pharmaceutical development company, which engages in the research and development associated with medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It operates through the following segments: Psychedelic Products, Cannabinoid Products, and Corporate. The Psychedelic Products segment is involved in the use of psychedelic medicine and therapies for the treatment of mental health disorders. The Cannabinoid Products segment focuses on the use of medicinal cannabinoid products. The Corporate segment consists of management of the organization, capital management, and management of resources. The company was founded on April 27, 2001 and is headquartered in Melbourne, Australia.

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on July 5, 2023 and is headquartered in Norwest, Australia.

MELBOURNE, Australia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic therapies for unmet medical needs, is pleased to announce that it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference.

Incannex to Participate in the Prestigious H.C. Wainwright 24th Annual Global Investment Conference

Incannex Appoints FDA Regulatory Affairs Expert Mr Robert B. Clark to the Board of Directors

Highlights: Incannex have engaged Curia to scale up cGMP fill-finish manufacture of IHL-216A Engagement of Curia follows achievement of "proof-of-concept" formulation development A patent has been filed on the composition of IHL-216A The first cGMP batch of IHL-216A manufactured at Curia will be used in a phase 1 clinical trial Incannex is targeting a pre-IND meeting with FDA in Q3 2022 to discuss the most efficient clinical trial development plan to achieve commercialisation for IHL-216A.  MELBOURNE, Australia , Aug. 2, 2022 /PRNewswire/ -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has engaged Curia Global, Inc. ('Curia') to further develop and manufacture GMP-grade IHL-216A, Incannex's proprietary inhaled drug product for the treatment of concussion and traumatic brain injury ('TBI').

Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

Clever Leaves Holdings Inc

Greenlane Holdings

Intercure Ltd

Tilray Brands

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.

5 Cannabis Stocks You Don't Want to Hit 'Snooze' On

Highlights: Bellberry human research ethics committee approved the phase 1 clinical trial investigating safety and pharmacokinetics of IHL-675A on July 20, 2022 The trial will be performed at CMAX Clinical Research, a dedicated and experienced clinical trial centre in Australia, and managed by Avance Clinical The trial will assess the pharmacokinetics, safety, and tolerability of combination cannabinoid drug IHL-675A Trial data will be applicable to regulatory submissions for all three IHL-675A development programs, rheumatoid arthritis, inflammatory bowel disease and lung inflammation Formulation and manufacturing of IHL-675A soft gel capsules for the clinical trial has been completed; long term stability studies are ongoing Patient recruitment is scheduled to commence in August 2022 MELBOURNE, Australia , July 21, 2022 /PRNewswire/ -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has received approval from the Bellberry Human Research Ethics Committee ('HREC') for a phase 1 clinical trial investigating its proprietary multi-use, anti-inflammatory drug IHL-675A. IHL-675A is a combination cannabinoid drug comprising cannabidiol ('CBD') and hydroxychloroquine ('HCQ') in a fixed dose combination.

Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A

MELBOURNE, Australia , June 27, 2022 /PRNewswire/ -- Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that Dr. Paul Liknaitzky, Head of Clinical Psychedelic Research at Monash University and Chief Principal Investigator for Incannex's psilocybin-assisted psychotherapy, will present an overview of progress achieved in Incannex's psychedelic medicine program at the H.C. Wainwright First Annual Mental Health Conference, taking place June 27, 2022.

Incannex to Present at the H.C. Wainwright First Annual Mental Health Conference

Highlights: IHL-42X reduced primary endpoint apnoea hypopnea index relative to baseline at all three doses that were assessed Low dose IHL-42X exhibited superior safety and efficacy metrics to mid and high doses Low dose IHL-42X reduced AHI by an average of 50.7% compared to baseline with 25% of participants experiencing a reduction in the apnoea hypopnea index of greater that 80% Oxygen desaturation index was reduced by 59.7% relative to baseline while taking low dose IHL-42X, improving sleep quality and reducing cardiovascular stress In low dose IHL-42X samples, THC concentrations in blood were well below the limits for impaired driving the morning after dose administration IHL-42X was well tolerated – low dose IHL-42X was observed to have a lower number of total treatment emergent adverse events than placebo Low dose IHL-42X reduced AHI substantially more effectively than is reported for the component active pharmaceutical ingredients, dronabinol and acetazolamide, as unregistered monotherapies. MELBOURNE, Australia , June 3, 2022 /PRNewswire/ -- Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has completed analysis of data from the phase 2 proof-of-concept clinical trial investigating IHL-42X for treatment of obstructive sleep apnoea ('OSA').

Incannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea

Aurora Cannabis

Canopy Growth

Flora Growth Corp

GrowGeneration Corp

Innovative Industrial Properties

Akerna Corp

Leafly Holdings

SNDL Inc.

What Happened With These 11 Cannabis Stocks This Week?

MELBOURNE, Australia , May 17, 2022 /PRNewswire/ -- Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it completed a highly constructive Pre-Investigational New Drug Application ('pre-IND') meeting with the U.S. Food and Drug Administration ('FDA') to discuss the development IHL-42X. IHL-42X is a fixed dose combination of dronabinol and acetazolamide that is being developed as a treatment for obstructive sleep apnoea ('OSA') in adults.

Incannex Announces Positive Pre-IND Meeting with U.S. FDA for IHL-42X for Obstructive Sleep Apnoea

MELBOURNE, Australia , May 12, 2022 /PRNewswire/ -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, advises that it has entered into a Share Sale and Purchase Agreement to acquire 100% of the issued share capital in APIRx Pharmaceuticals USA, LLC (APIRx) (Acquisition).  The stakeholders in APIRx (Sellers) will be issued a total of 218,169,506 new Shares at a value of $0.573 per Share the sale and purchase of APIRx, the price agreed at the signing of the binding terms sheet and announced on March 24, 2022.

Incannex Completes Share Sale and Purchase Agreement to Wholly Acquire APIRx Pharmaceuticals USA, LLC

Highlights: The study compared IHL-216A to its component drugs, cannabidiol (CBD) and isoflurane, in a model developed in collaboration with the US National Football League (NFL) IHL-216A restored spatial memory after twenty-four hours in injured rodent models whilst those that only received the vehicle as treatment did not have restored spatial memory Treatment with CBD only partially restored spatial memory compared to IHL-216A, further supporting the benefits of Incannex's patented novel drug combination compared to CBD alone Incannex now targets a pre-IND meeting with the U.S. FDA in Q3 2022 to discuss an expedited clinical trial program. MELBOURNE, Australia , May 10, 2022 /PRNewswire/ -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex" or the 'Company'), a clinical stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that IHL-216A was observed to have a strong neuroprotective effect in a widely known model of sports concussion.

Incannex announces IHL-216A observed to have a neuroprotective effect in a rodent model of sports concussion; rapidly restores spatial memory post-concussion

Highlights: Positive phase 2a clinical trial results for IHL-42X with 60% of trial participants experiencing at least a 55% reduction in the Apnoea Hypopnea Index ('AHI') 20% of IHL-42X clinical trial participants experienced a reduction in AHI of greater than 80% completes comprehensive in vivo study on the neuroprotective capability of IHL-216A with results being analysed to be released within 2-3 weeks treatment commences in the phase 2a clinical trial to assess psilocybin and specialised psychotherapy for the treatment of generalised anxiety disorder initiates a second clinical psychedelic therapy program in a leading-edge academic field of virtual reality (VR) exposure response therapy (ERP) and psychedelics executed a term sheet with binding commercial terms to wholly acquire APIRx Pharmaceuticals at fixed price of A$0.573 (equivalent to approximately US$10.45 per ADS), which has 22 active cannabinoid R&D projects underpinned by patents patented CanQuit (CBD + nicotine) medicated chewing gum (APIRx product) for smoking cessation has the potential to disrupt the nicotine chewing gum market, which currently exceeds US$5B in sales per annum Incannex lists American Depositary Shares (ADSs) on NASDAQ under stock code "IXHL" Incannex adequately funded with cash of $40.0M following completion of loyalty option offer to existing shareholders after quarter's end in April 2022. MELBOURNE, Australia , April 28, 2022 /PRNewswire/ -- Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical stage pharmaceutical development company, is pleased to provide its quarterly activities report and appendix 4C for the period ended 31st March 2022.

Quarterly Activities Report and Appendix 4C Cash Flow Statement

MELBOURNE, Australia , April 28, 2022 /PRNewswire/ -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that it has finalised its loyalty option offer to shareholders to raise A$23.6M.  Loyalty options expired on April 22, 2022 and a total of 67.3M new shares are to be issued shortly as a result of the entitlement program.

Incannex Completes Loyalty Option Program to Raise A$23.6M; Current Cash at Bank is Approximately A$40.0M

Incannex Healthcare Ltd. IXHL, -4.23% shares jumped 7% after the Australia-based cannabinoid and psychedelic compound medicine development company said it would pay $93.3 million to acquire APIRx Pharmaceutical USA LLC, a pharmaceutical medicinal cannabinoid product development company.

Incannex Healthcare rallies after airing plan to buy cannabis medicine company APIRx

Highlights: APIRx has twenty-two (22) active clinical and pre-clinical research and development projects therapeutic candidates are targeted at treating pain, dementia, Parkinson's disease, restless leg syndrome, gastrointestinal diseases, periodontitis, addiction disorders, skin conditions and ophthalmic conditions therapeutic candidates are underpinned by an extensive intellectual property portfolio that includes 19 granted patents and 23 pending patents proposed acquisition price of US$93.3M in all scrip transaction the transaction affirms Incannex's position as a global leader in the fields of cannabinoid, psychedelic, and combination pharmaceuticals. MELBOURNE, Australia , March 24, 2022 /PRNewswire/ -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that it has executed a term sheet with binding commercial terms to wholly acquire APIRx Pharmaceutical USA, LLC ('APIRx'), subject to shareholder approval under ASX listing Rule 7.1.

Incannex to Acquire APIRx Pharmaceuticals USA, LLC

Profit-taking after a big gain earlier this week took its toll.

Why Incannex Healthcare Stock Crashed Today

Here's what investors intrigued by today's 100% rise in Incannex Healthcare and IXHL stock may want to know about this company. The post IXHL Stock Alert: 7 Things to Know as Incannex Healthcare Skyrockets Too appeared first on InvestorPlace.

IXHL Stock Alert: 7 Things to Know as Incannex Healthcare Skyrockets Too

Incannex Healthcare Ltd (NASDAQ: IXHL) is soaring Tuesday on abnormally-high volume. The stock has been extremely volatile since the company released a preliminary analysis of data from its phase 2 clinical trial investigating its novel cannabinoid combination product, IHL-42X, for the.

What's Going On With Incannex Healthcare's Stock Today?

AFC Gamma

High Tide

Village Farms International

The Valens Co

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we make our way through 2022.

The 7 Hottest Cannabis Stocks To Watch This Week

MELBOURNE, Australia, March 10, 2022 /PRNewswire/ -- Highlights: 20% of trial participants experienced a reduction in AHI of greater than 80% (range: 82.7% to 91.5%) during at least one treatment compared to baseline 60% of trial participants experienced a reduction in AHI of greater than 50% (range: 55.0% to 91.5%) during at least one treatment compared to baseline Average of low, mid and high-dose IHL-42X reduced AHI in trial participants by 44.4%, compared to baseline IHL-42X was observed to be well tolerated in the clinical trial IHL-42X has the potential to reduce disease severity, resulting in improved sleep quality, multiple major health benefits and increased quality of life The Company has been granted a pre-IND meeting with FDA on May 11, 2022 (U.S. EST) Planning commences for pivotal clinical trials to commence after opening an IND with FDA. Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced the completion of a preliminary analysis of data from its phase 2, proof-of-concept clinical trial investigating novel cannabinoid combination product, IHL-42X, for the treatment of obstructive sleep apnoea ('OSA').

Incannex observes substantial reduction in AHI in preliminary results of clinical trial assessing IHL-42X in patients with OSA; proceeds to pivotal studies

Cronos Group

Hydrofarm Holdings Group

Jazz Pharmaceuticals

OrganiGram Holdings Inc.

Zynerba Pharmaceuticals

Cannabis Sector Kicks Off March With a Blast of Q4 Earnings

MELBOURNE, Australia, March 3, 2022 /PRNewswire/ -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced it has executed a license agreement with Monash University ('Monash University' or 'Monash') to develop a novel treatment that combines Virtual Reality ('VR') and psychedelics. This marks the initiation of a second clinical psychedelic therapy program.

Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics

MELBOURNE, Australia, Feb. 28, 2022 /PRNewswire/ -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that American Depositary Shares ('ADS') representing its ordinary shares have commenced trading on the Nasdaq Global Market ('Nasdaq') under the ticker symbol 'IXHL'. Each IXHL ADS represents 25 ordinary shares of the Company.

Incannex Completes Listing of American Depositary Shares on Nasdaq; Rings Nasdaq Closing Bell

News for Incannex Healthcare Inc Stock (IXHL)